U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07422675) titled 'SAD Study in Patients With Parkinson's Disease and Motor Fluctuations' on Feb. 05.
Brief Summary: This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
PARKINSON DISEASE (Disorder)
Advanced Parkinson's Disease
Intervention:
DRUG: SER-252 (PEOZ-apomorphine)
SER-252 drug product consists of 20mg lyophilized apomorphine equivalent in SER-252 drug substance in a sterile vial for reconstitution with a diluent product containing 15mM acetate buffer at pH 6.0 and 7% tr...